Imatinib-induced gastric antral vascular ectasia in three patients with chronic myeloid leukaemia

Jeremy Ong; David T Yeung; Robin J A Filshie; Timothy P Hughes; Harshal Nandurkar

doi:10.1007/s12185-015-1824-y

Imatinib-induced gastric antral vascular ectasia in three patients with chronic myeloid leukaemia

Jeremy Ong, David T Yeung, Robin J A Filshie, Timothy P Hughes, Harshal Nandurkar

Research output: Contribution to journal › Article › Other › peer-review

6 Citations (Scopus)

Abstract

Imatinib is generally well tolerated, but gastric antral vascular ectasia (GAVE) remains a rare but significant complication of imatinib therapy. Whilst this complication has been described in other disease settings, only one other case of GAVE has been reported in a chronic myeloid leukaemia (CML) patient receiving imatinib. Herein, we present three CML patients with GAVE complicating imatinib therapy. In all cases, GAVE resolved only with cessation of imatinib. This confirms a causal relationship between GAVE and imatinib. GAVE should be considered as a possible cause of anaemia and upper gastrointestinal bleeding in patients receiving imatinib therapy.

Original language	English
Pages (from-to)	639-642
Number of pages	4
Journal	International Journal of Hematology
Volume	102
Issue number	5
DOIs	https://doi.org/10.1007/s12185-015-1824-y
Publication status	Published - 2 Jul 2015
Externally published	Yes

Keywords

Chronic myeloid leukaemia
Gastric antral vascular ectasia
Imatinib
Tyrosine kinase inhibitor

Access to Document

10.1007/s12185-015-1824-y

Cite this

@article{321eef7c3d1f46ad8d83edf0fb8fccb5,

title = "Imatinib-induced gastric antral vascular ectasia in three patients with chronic myeloid leukaemia",

abstract = "Imatinib is generally well tolerated, but gastric antral vascular ectasia (GAVE) remains a rare but significant complication of imatinib therapy. Whilst this complication has been described in other disease settings, only one other case of GAVE has been reported in a chronic myeloid leukaemia (CML) patient receiving imatinib. Herein, we present three CML patients with GAVE complicating imatinib therapy. In all cases, GAVE resolved only with cessation of imatinib. This confirms a causal relationship between GAVE and imatinib. GAVE should be considered as a possible cause of anaemia and upper gastrointestinal bleeding in patients receiving imatinib therapy.",

keywords = "Chronic myeloid leukaemia, Gastric antral vascular ectasia, Imatinib, Tyrosine kinase inhibitor",

author = "Jeremy Ong and Yeung, \{David T\} and Filshie, \{Robin J A\} and Hughes, \{Timothy P\} and Harshal Nandurkar",

year = "2015",

month = jul,

day = "2",

doi = "10.1007/s12185-015-1824-y",

language = "English",

volume = "102",

pages = "639--642",

journal = "International Journal of Hematology",

issn = "0925-5710",

publisher = "Springer",

number = "5",

}

TY - JOUR

T1 - Imatinib-induced gastric antral vascular ectasia in three patients with chronic myeloid leukaemia

AU - Ong, Jeremy

AU - Yeung, David T

AU - Filshie, Robin J A

AU - Hughes, Timothy P

AU - Nandurkar, Harshal

PY - 2015/7/2

Y1 - 2015/7/2

N2 - Imatinib is generally well tolerated, but gastric antral vascular ectasia (GAVE) remains a rare but significant complication of imatinib therapy. Whilst this complication has been described in other disease settings, only one other case of GAVE has been reported in a chronic myeloid leukaemia (CML) patient receiving imatinib. Herein, we present three CML patients with GAVE complicating imatinib therapy. In all cases, GAVE resolved only with cessation of imatinib. This confirms a causal relationship between GAVE and imatinib. GAVE should be considered as a possible cause of anaemia and upper gastrointestinal bleeding in patients receiving imatinib therapy.

AB - Imatinib is generally well tolerated, but gastric antral vascular ectasia (GAVE) remains a rare but significant complication of imatinib therapy. Whilst this complication has been described in other disease settings, only one other case of GAVE has been reported in a chronic myeloid leukaemia (CML) patient receiving imatinib. Herein, we present three CML patients with GAVE complicating imatinib therapy. In all cases, GAVE resolved only with cessation of imatinib. This confirms a causal relationship between GAVE and imatinib. GAVE should be considered as a possible cause of anaemia and upper gastrointestinal bleeding in patients receiving imatinib therapy.

KW - Chronic myeloid leukaemia

KW - Gastric antral vascular ectasia

KW - Imatinib

KW - Tyrosine kinase inhibitor

UR - https://www.scopus.com/pages/publications/84947026539

U2 - 10.1007/s12185-015-1824-y

DO - 10.1007/s12185-015-1824-y

M3 - Article

C2 - 26134364

SN - 0925-5710

VL - 102

SP - 639

EP - 642

JO - International Journal of Hematology

JF - International Journal of Hematology

IS - 5

ER -

Imatinib-induced gastric antral vascular ectasia in three patients with chronic myeloid leukaemia

Abstract

Keywords

Access to Document

Other files and links

Cite this